BioCentury
ARTICLE | Company News

Eisai obtains license from Elan

October 11, 2000 7:00 AM UTC

ELN granted Eisai (Tokyo, Japan) an exclusive license to develop and market in Japan its NeuroBloc botulinum toxin type B to treat cervical dystonia. ELN will manufacture and supply the product. ...